Compare VanEck Junior Gold Miners (GDXJ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Neurocrine Biosciences Inc — how do they compare? VanEck Junior Gold Miners trades at $113.98 (market cap $8.22B), while Neurocrine Biosciences Inc trades at $142.45 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and VanEck Junior Gold Miners is more actively traded (3,212,198 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GDXJ | NBIX | |
|---|---|---|
Market Cap | $8.22B | $14.36B |
Volume | 3,212,198 | 1,237,180 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $185.50 |
52-Week Low | $87.56 | $123.10 |
Typical Hold Time | 41 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $113.02, up 3.56% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF is undergoing significant rebalancing, with multiple junior mining companies added in September 2026, potentially increasing diversification. Key support lies at $110, with resistance at $113. Financial ratios are not applicable as this is a fund tracking an index of gold mining equities.
The outlook remains cautious due to bearish technicals, though inclusion of new holdings may attract flows. Risks include gold price volatility and mining sector operational challenges. Analyst views on constituent stocks vary, but the ETF offers exposure to small-cap gold miners, which can be high-risk, high-reward during gold rallies.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
